A. Luscher, H. P. de Koning and P. Maser Pages 555 - 567 ( 13 )
Trypanosoma brucei rhodesiense and T. b. gambiense are the causative agents of sleeping sickness, a fatal disease that affects 36 countries in sub-Saharan Africa. Nevertheless, only a handful of clinically useful drugs are available. These drugs suffer from severe side-effects. The situation is further aggravated by the alarming incidence of treatment failures in several sleeping sickness foci, apparently indicating the occurrence of drug-resistant trypanosomes. Because of
Trypanosoma brucei,sleeping sickness,functional genomics,drug target,chemotherapy,drug resistance
, , University of Glasgow, Joseph Black Building, G12 8QQ Glasgow, UK.